Bio-Rad Laboratories, Inc. - BIO STOCK NEWS

Bio-Rad Laboratories reported Q3 2024 financial results with total net sales of $649.7 million, up 2.8% from Q3 2023. Clinical Diagnostics segment saw a 5.6% increase to $388.8 million, while Life Science segment decreased 1.0% to $260.9 million. The company's gross margin improved to 54.8% from 53.1%. Income from operations was $64.5 million, down from $90.9 million in Q3 2023. Net income significantly increased to $653.2 million ($23.34 per share), largely due to changes in fair market value of Sartorius AG investment. The company maintains its full-year 2024 outlook with expected non-GAAP revenue decline of 2.5-4.0% on a currency-neutral basis.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced it will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, after market close. The company will host a conference call at 2 PM Pacific Time (5 PM Eastern Time) on the same day to discuss the results.

Interested parties can participate in the call by dialing 800-579-2543 within the U.S. or 785-424-1789 outside the U.S., using the access code: BIORAD. Additionally, a live webcast of the conference call will be available in the "Investor Relations" section of Bio-Rad's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be accessible for up to one year.

Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, has announced its participation in Wells Fargo's 2024 Healthcare Conference. CEO Norman Schwartz and CFO Roop K. Lakkaraju will engage in a fireside chat on Wednesday, September 4, at 2:15 PM Eastern Time (11:15 AM Pacific Time).

The event will be accessible via live webcast and a replay will be available afterwards. Interested parties can find both the live stream and replay in the Investor Relations section of Bio-Rad's website at bio-rad.com. This participation underscores Bio-Rad's commitment to engaging with investors and sharing insights about the company's operations and future prospects.

Bio-Rad Laboratories (NYSE: BIO and BIO.B) has announced the appointment of Jon DiVincenzo as President and Chief Operating Officer, effective September 9, 2024. DiVincenzo, who brings over 30 years of industry experience, will replace the retiring Andy Last. He joins Bio-Rad from Labcorp Holdings Inc., where he most recently served as Executive Vice President and President of Central Laboratories and International.

DiVincenzo's extensive background includes leadership roles at PerkinElmer, Enzymatics, and EMD Millipore. His experience spans strategic, operational, and commercial organizations in both life science and clinical diagnostics. Norman Schwartz, Bio-Rad's Chairman and CEO, expressed enthusiasm about DiVincenzo's appointment, highlighting his track record in operations, marketing, and product development as integral to the company's future success.

Bio-Rad Laboratories (NYSE: BIO and BIO.B) reported Q2 2024 financial results with total net sales of $638.5 million, a 6.3% decrease from Q2 2023. The Life Science segment saw a 16.5% decrease, while Clinical Diagnostics increased by 2.1%. Gross margin improved to 55.6% from 53.2% in Q2 2023. The company reported a net loss of $2,165.5 million, primarily due to changes in the fair market value of its Sartorius AG investment. Non-GAAP net income was $88.5 million, or $3.11 per diluted share. Bio-Rad updated its 2024 outlook, expecting a 2.5-4.0% revenue decline and a non-GAAP operating margin of 12.0-13.0%. The board authorized an additional $500 million for share repurchases.

Bio-Rad Laboratories (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced it will report its financial results for the second quarter of 2024 on Thursday, August 1, 2024, after market close. The company will host a conference call at 2 PM Pacific Time (5 PM Eastern Time) on the same day to discuss the results. Investors can participate by dialing 800-343-4849 (U.S.) or 203-518-9856 (outside U.S.) with the access code: BIORAD. A live webcast will be available on the company's website, and a replay will be accessible for up to a year.

Bio-Rad Laboratories has appointed Anette Engelhardt as Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024. Engelhardt joins from Cepheid, where she was a Senior Vice President and General Manager. At Cepheid, she managed emerging growth opportunities and led global R&D, strategy, and product management. She has significant experience in the diagnostics field, having held senior roles at bioMerieux and served as CEO of AB BIODISK. Andy Last, Bio-Rad’s Executive VP and COO, expressed confidence in Engelhardt's ability to drive the company's clinical diagnostics strategy and product development.

Bio-Rad Laboratories, a leader in life science research and clinical diagnostics, announced that CEO Norman Schwartz and CFO Roop K. Lakkaraju will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for June 6, 2024, at 10:30 AM ET (7:30 AM PT). A live webcast and replay will be accessible via the Investor Relations section of Bio-Rad’s website.

Bio-Rad Laboratories, Inc. reported first-quarter 2024 financial results with total net sales of $610.8 million, a decrease of 9.8% compared to the same period in 2023. While Life Science segment sales dropped by 25.3%, Clinical Diagnostics segment sales increased by 4.7%. Net income for the quarter was $383.9 million, or $13.45 per share, compared to $69.0 million, or $2.32 per share, in 2023. Bio-Rad remains cautiously optimistic about a gradual biopharma market recovery and confident in their long-term strategy.